4.57
price down icon0.87%   -0.04
after-market Dopo l'orario di chiusura: 4.56 -0.01 -0.22%
loading
Precedente Chiudi:
$4.61
Aprire:
$4.61
Volume 24 ore:
231.20K
Relative Volume:
0.55
Capitalizzazione di mercato:
$211.70M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-1.718
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+8.29%
1M Prestazione:
+12.01%
6M Prestazione:
-1.93%
1 anno Prestazione:
-75.32%
Intervallo 1D:
Value
$4.43
$4.61
Intervallo di 1 settimana:
Value
$4.145
$4.7497
Portata 52W:
Value
$2.235
$19.33

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Nome
4 D Molecular Therapeutics Inc
Name
Telefono
(510) 505-2680
Name
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Name
Dipendente
227
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
FDMT's Discussions on Twitter

Confronta FDMT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
4.57 213.56M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-13 Downgrade BMO Capital Markets Outperform → Market Perform
2024-11-21 Iniziato Morgan Stanley Underweight
2024-09-23 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-04-15 Iniziato Barclays Overweight
2024-02-07 Ripresa Goldman Buy
2023-10-26 Iniziato RBC Capital Mkts Outperform
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-10-18 Aggiornamento Leerink Partners Market Perform → Outperform
2023-07-05 Iniziato Chardan Capital Markets Buy
2023-01-30 Iniziato BMO Capital Markets Outperform
2022-11-18 Iniziato H.C. Wainwright Buy
2022-11-15 Aggiornamento Goldman Neutral → Buy
2022-08-12 Downgrade SVB Leerink Outperform → Mkt Perform
2022-06-22 Iniziato Jefferies Buy
2022-01-04 Iniziato SVB Leerink Outperform
2021-01-05 Iniziato BofA Securities Buy
2021-01-05 Iniziato Evercore ISI Outperform
2021-01-05 Iniziato Goldman Neutral
Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

pulisher
Jul 25, 2025

What drives 4D Molecular Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

4D Molecular Therapeutics Inc. Stock Analysis and ForecastTremendous portfolio expansion - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionLong Term Secure Gain Stocks - Newser

Jul 25, 2025
pulisher
Jul 24, 2025

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire Inc.

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about 4D Molecular Therapeutics Inc. stockUnrivaled growth potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

Is 4D Molecular Therapeutics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 19, 2025
pulisher
Jul 18, 2025

Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025
pulisher
Jul 17, 2025

4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jul 11, 2025
pulisher
Jul 11, 2025

Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

4D Molecular to layoff about 25% of workforce - MSN

Jul 10, 2025
pulisher
Jul 07, 2025

Promising Penny Stocks To Consider In July 2025 - simplywall.st

Jul 07, 2025
pulisher
Jul 06, 2025

4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat

Jul 06, 2025
pulisher
Jul 05, 2025

Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 05, 2025
pulisher
Jul 04, 2025

4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

4D Molecular Therapeutics Updates Phase 3 Program for Wet AMD - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals

Jul 02, 2025
pulisher
Jul 02, 2025

4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener

Jul 02, 2025
pulisher
Jul 02, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire

Jul 02, 2025
pulisher
Jul 02, 2025

4D Molecular to layoff about 25% of workforce (FDMT:NASDAQ) - Seeking Alpha

Jul 02, 2025
pulisher
Jun 30, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jun 28, 2025
pulisher
Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025
pulisher
Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025
pulisher
Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):